Dated evidence feed
What selected attributable sources posted or changed, kept distinct from claims about safety or effectiveness. This is not a complete or continuously monitored peptide-news feed.
Regulatory · BPC-157 + 6 more
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.
Clinical trials · Survodutide
ClinicalTrials.gov lists an active, not recruiting Survodutide study sponsored by Boehringer Ingelheim.
Source: ClinicalTrials.gov ↗
Clinical trials · Maridebart cafraglutide
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.
Source: ClinicalTrials.gov ↗
Clinical trials · Mazdutide
ClinicalTrials.gov lists a Mazdutide study that is not yet recruiting sponsored by West China Hospital.
Source: ClinicalTrials.gov ↗
Clinical trials · Retatrutide
ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.
Source: ClinicalTrials.gov ↗
Clinical trials · Cagrilintide
ClinicalTrials.gov lists a recruiting Cagrilintide study sponsored by Novo Nordisk A/S.
Source: ClinicalTrials.gov ↗
Clinical trials · Elamipretide
ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.
Source: ClinicalTrials.gov ↗
Clinical trials · Petrelintide
ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.
Source: ClinicalTrials.gov ↗
Safety · Semaglutide + 1 more
FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.
Clinical trials · Pemvidutide
ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.
Source: ClinicalTrials.gov ↗
Regulatory · Semaglutide + 2 more
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.
Regulatory · Retatrutide + 1 more
FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.
Regulatory · Semaglutide
FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records.
Clinical trials · BPC-157
ClinicalTrials.gov lists a recruiting BPC-157 study sponsored by Hudson Biotech.
Source: ClinicalTrials.gov ↗
Safety · Semaglutide + 2 more
FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.